1. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
- Author
-
VandeVrede, Lawren, La Joie, Renaud, Horiki, Sheena, Mundada, Nidhi S., Koestler, Mary, Hwang, Ji-Hye, Ljubenkov, Peter A., Rojas, Julio C., Rabinovici, Gil D., Boxer, Adam L., and Seeley, William W.
- Subjects
ADUCANUMAB ,CLINICAL pathology ,LEWY body dementia ,ALZHEIMER'S disease ,PREFRONTAL cortex - Abstract
Aducanumab is one example of a class of amyloid-targeting antibodies proposed as treatment for early AD [[4], [9]], but few clinicopathological studies are available from patients given these treatments. Keywords: Alzheimer's disease; Amyloid; Lewy body disease; Aducanumab; Clinicopathological correlation EN Alzheimer's disease Amyloid Lewy body disease Aducanumab Clinicopathological correlation 777 781 5 10/12/23 20231101 NES 231101 Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00401-023-02631-8. The extensive tau neurofibrillary pathology suggests that either insufficient amyloid-lowering was achieved initially (remaining > 25 CL) or that tau spreading and propagation continue after amyloid-lowering unless maintenance dosing is administered. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF